Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
80.28
+2.57 (3.31%)
At close: Nov 25, 2025, 4:00 PM EST
81.85
+1.57 (1.96%)
After-hours: Nov 25, 2025, 6:59 PM EST
Corcept Therapeutics Employees
Corcept Therapeutics had 500 employees as of December 31, 2024. The number of employees increased by 148 or 42.05% compared to the previous year.
Employees
500
Change (1Y)
148
Growth (1Y)
42.05%
Revenue / Employee
$1,482,344
Profits / Employee
$209,312
Market Cap
8.44B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500 | 148 | 42.05% |
| Dec 31, 2023 | 352 | 53 | 17.73% |
| Dec 31, 2022 | 299 | 61 | 25.63% |
| Dec 31, 2021 | 238 | 2 | 0.85% |
| Dec 31, 2020 | 236 | 30 | 14.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CORT News
- 21 days ago - Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update - Business Wire
- 4 weeks ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 5 weeks ago - Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment - Business Wire
- 5 weeks ago - Corcept Transition To New Specialty Pharmacy Well Underway - Seeking Alpha
- 6 weeks ago - Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 7 weeks ago - Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
- 2 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga